



GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業（開曼）控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 6998)

NOTIFICATION LETTER 通知信函

26 April 2024

Dear Registered holder(s),

GENOR BIOPHARMA HOLDINGS LIMITED (the “Company”)

– Notice of Publication of 2023 Annual Report, Circular, Proxy Form for Annual General Meeting (the “Current Corporate Communications”) and 2023 Environmental, Social and Governance Report

The English and Chinese versions of the Company’s Current Corporate Communications are available on the Company’s website at www.genorbio.com and the website of Hong Kong Exchanges and Clearing Limited (the “HKEX”) at www.hkexnews.hk.

Shareholders may at any time choose to receive free of charge Corporate Communications ^(Note) either in printed form, or read the website version; and either in English language version only, Chinese language version only or both language versions, notwithstanding any wish to the contrary they have previously conveyed to the Company. If you want to receive a printed version of the Current Corporate Communications, please complete the Change Request Form on the reverse side and send it to the Company c/o Computershare Hong Kong Investor Services Limited (the “**Hong Kong Share Registrar**”) by using the mailing label at the bottom of the Change Request Form (no need to affix a stamp if posted in Hong Kong; otherwise, please affix an appropriate stamp). The address of the Hong Kong Share Registrar is 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong. The Change Request Form may also be downloaded from the Company’s website at www.genorbio.com or the website of HKEX at www.hkexnews.hk.

If you would like to change your choice of language or means of receipt of the Company’s Corporate Communications in future, please write to the Company c/o the Hong Kong Share Registrar or send an email at genorbio.ecom@computershare.com.hk. Even if you have chosen (or are deemed to have consented) to receive Corporate Communications via website version but for any reason you have difficulty in receiving or gaining access to the Current Corporate Communications, the Company will promptly upon your request send the Current Corporate Communications to you in printed form free of charge.

The 2023 Environmental, Social and Governance Report, published in electronic form only, is also available on the Company’s website and the website of the HKEX. If you have difficulty in gaining access to the 2023 Environmental, Social and Governance Report in electronic form and wish to receive a printed copy, you may submit your request to the Company c/o the Hong Kong Share Registrar by post at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong or by email to genorbio.ecom@computershare.com.hk.

Should you have any queries relating to any of the above matters, please call the Hong Kong Share Registrar’s telephone hotline at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays or send an email to genorbio.ecom@computershare.com.hk.

Yours faithfully,

For and on behalf of

GENOR BIOPHARMA HOLDINGS LIMITED

Dr. Guo Feng

Executive Director, Chief Executive Officer and Chairman

Note: Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to, (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

各位登記股東：

嘉和生物藥業（開曼）控股有限公司（「本公司」）

– 有關 2023 年報、股東週年大會通函、代表委任表格（「本次公司通訊」）及 2023 環境、社會及管治報告之發佈通知

本公司的本次公司通訊的中、英文版本已上載於本公司網站 www.genorbio.com 及香港交易及結算所有限公司（「香港交易所」）網站 www.hkexnews.hk。

儘管閣下早前曾向本公司作出公司通訊 ^(附註) 收取方式或語言版本的選擇，但仍可以隨時更改有關選擇，轉為以印刷本或網上方式收取或只收取英文印刷本、或只收取中文印刷本、或同時收取中、英文印刷本，費用全免。如閣下欲收取本次公司通訊之印刷本，請閣下填妥在本函背面的更改表格，並使用更改表格下方之郵寄標籤經由香港中央證券登記有限公司（「香港股份過戶登記處」）寄回本公司（如在香港投寄，毋須貼上郵票；否則，請貼上適當的郵票）。香港股份過戶登記處地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。更改表格亦可於本公司網站 www.genorbio.com 或香港交易所網站 www.hkexnews.hk 內下載。

如閣下欲更改日後收取本公司通訊之語言版本或收取方式，請以書面經由香港股份過戶登記處送交至本公司或以電郵方式發送至 genorbio.ecom@computershare.com.hk。如閣下已選擇（或被視為已同意）以網上方式收取公司通訊但因任何理由未能閱覽載於網站的本次公司通訊，閣下只要提出要求，我們將盡快向閣下寄上本次公司通訊的印刷版本，費用全免。

僅以電子形式發佈的 2023 環境、社會及管治報告亦已於本公司網站及香港交易所網站登載。如閣下於接收以電子形式發佈的 2023 環境、社會及管治報告出現困難及欲索取印刷本，閣下可向香港股份過戶登記處（郵寄至香港灣仔皇后大道東 183 號合和中心 17M 樓或電郵至 genorbio.ecom@computershare.com.hk）提出有關要求以轉交本公司。

如對本函內容有任何疑問，請致電香港股份過戶登記處電話熱線 (852) 2862 8688，辦公時間為星期一至星期五（香港公眾假期除外）上午九時正至下午六時正或電郵至 genorbio.ecom@computershare.com.hk。

代表

嘉和生物藥業（開曼）控股有限公司

郭峰博士

執行董事、行政總裁兼主席

謹啟

二零二四年四月二十六日

附註：公司通訊乃指公司發出或將予發出以供其任何證券持有人參照或採取行動的任何文件，其中包括但不限於：(a) 董事會報告、年度賬目連同核數師報告及（如適用）財務摘要報告；(b) 中期報告及（如適用）中期摘要報告；(c) 會議通告；(d) 上市文件；(e) 通函；及(f) 代表委任表格。

JCYH-26042024-1(0)

**Change Request Form 更改表格**

To: **GENOR BIOPHARMA HOLDINGS LIMITED (the "Company")**
(Stock Code: 6998)
c/o Computershare Hong Kong Investor Services Limited
17M Floor, Hopewell Centre,
183 Queen's Road East,
Wan Chai, Hong Kong

致: **嘉和生物藥業(開曼)控股有限公司(「本公司」)**
(股份代號: 6998)
經香港中央證券登記有限公司
香港灣仔
皇后大道東 183 號
合和中心 17M 樓

I/We would like to receive all Corporate Communications* of the Company in the manner as indicated below:
本人/我們希望以下列方式收取 貴公司之所有公司通訊*:

(Please mark (X) in **ONLY ONE** of the following boxes) (請從下列選擇中, 僅在其中一個空格內劃上「X」號)

- to read all Corporate Communications published on the website of the Company at www.genorbio.com (the "Website Version") instead of receiving printed copies, and to receive a written notification by post for the publication of the relevant Corporate Communications on the website of the Company; **OR**
閱覽在 貴公司網站 (www.genorbio.com) 登載的公司通訊(「網上版本」), 以代替收取印刷本, 並以郵遞收取已在 貴公司網站登載的公司通訊之書面通知; **或**
- to receive the **printed English version** of all Corporate Communications **ONLY**; **OR**
僅收取所有公司通訊文件之**英文印刷本**; **或**
- to receive the **printed Chinese version** of all Corporate Communications **ONLY**; **OR**
僅收取所有公司通訊文件之**中文印刷本**; **或**
- to receive both **printed English and Chinese versions** of all Corporate Communications.
同時收取所有公司通訊文件之**英文及中文印刷本**。

Full Name

姓名

Signature

簽名

Contact telephone number

聯絡電話號碼

Date

日期

Notes 附註:

- Please complete all your details clearly.
請 閣下清楚填寫所有資料。
 - If your shares are held in joint names, the shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign on this Change Request Form in order to be valid.
如屬聯名股東, 則本更改表格須由該名於本公司股東名冊上就聯名持有股份之其姓名位列首位的股東簽署, 方為有效。
 - Any form with more than one box marked (X), with no box marked (X), with no signature or otherwise incorrectly completed will be void.
如在本表格作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面填寫不正確, 則本更改表格將會作廢。
 - The above instruction will apply to all future Corporate Communications to be sent to shareholders of the Company until you notify otherwise by reasonable notice in writing (not less than 7 days) to the Company c/o the Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at genorbio.ecom@computershare.com.hk.
上述指示適用於日後寄發予本公司股東之所有公司通訊, 直至 閣下發出合理時間的書面通知(最短不少於 7 日)予本公司香港股份過戶登記處 - 「香港中央證券登記有限公司」(地址為香港灣仔皇后大道東 183 號合和中心 17M 樓)或以電郵發送至 genorbio.ecom@computershare.com.hk 另作選擇為止。
 - Shareholders are entitled to change the choice of means of receipt and language of Corporate Communications at any time by reasonable notice in writing (not less than 7 days) to the Company c/o the Hong Kong Share Registrar (at the above address) or by email at genorbio.ecom@computershare.com.hk.
股東有權隨時發出合理時間的書面通知(最短不少於 7 日)予本公司香港證券登記處(上述地址)或以電郵發送至 genorbio.ecom@computershare.com.hk, 要求更改有關公司通訊的語言版本及收取方式。
 - For the avoidance of doubt, we do not accept any special instructions written on this Change Request Form.
為免存疑, 任何在本更改表格上的額外手寫指示, 本公司將不予處理。
- * Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to, (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.
公司通訊乃指公司發出或將予發出以供其任何證券持有人參照或採取行動的任何文件, 其中包括但不限於: (a) 董事會報告、年度賬目連同核數師報告及(如適用)財務摘要報告; (b) 中期報告及(如適用)中期摘要報告; (c) 會議通告; (d) 上市文件; (e) 通函; 及(f) 代表委任表格。

✂

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited

香港中央證券登記有限公司

Freeport No. 簡便回郵號碼: 37

Hong Kong 香港

Please cut the mailing label and stick it on an envelope
to return this Request Form to us.

No postage is necessary if posted in Hong Kong.

當 閣下寄回本申請表格時, 請將郵寄標籤剪貼於信封上。
如在本港投寄, 閣下無需支付郵費或貼上郵票。

Get in touch with us 與我們聯繫

Send us an enquiry 垂詢
Rate our service 評價
Lodge a complaint 投訴



Contact Us 聯繫我們

www.computershare.com/hk/contact